Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 8:16:14.
doi: 10.1186/s12948-018-0093-8. eCollection 2018.

Sublingual grass allergen specific immunotherapy: a retrospective study of clinical outcome and discontinuation

Christer Janson  1 , Fredrik Sundbom  1 , Peter Arvidsson  2 , Mary Kämpe  1
Affiliations

Sublingual grass allergen specific immunotherapy: a retrospective study of clinical outcome and discontinuation

Christer Janson et al. Clin Mol Allergy. .

Abstract

Background: Sublingual immunotherapy (SLIT) is effective, tolerable, and convenient for many allergic patients. Still, real-world evidence is scarce and the aim of this study is to assess the patient reported outcome of treatment with SLIT against grass pollen allergy in a consecutive patient population.

Methods: Patients (n = 329) who were confirmed to be allergic to timothy grass and had been prescribed SLIT were consecutively enrolled in the study and completed a questionnaire online or in hard copy.

Results: 207 (62.9%) patients responded to the questionnaire. The female/male ratio was 105/102 with a mean age of 39 ± 11 years (range 19-70 years). 113 (55%) patients reported they had completed the full 3-year treatment period, 49 (24%) were still on treatment, and 45 (22%) had discontinued treatment prematurely. Respondents who had completed the full treatment period reported that their allergy symptoms in the most recent grass pollen season had improved to a larger extent than subjects still on treatment or discontinuing the treatment prematurely. Improvement of asthma was twice as common among patients who completed compared to discontinued treatment (42 vs. 20%). Younger age (37 ± 12 vs. 41 ± 11 years, p < 0.001) and a higher prevalence of reported oral and/or gastrointestinal side effects (49 vs. 24%, p = 0.02) characterised the group that terminated SLIT. Forgetfulness was the most commonly reported specific reason.

Conclusion: Treatment perseverance resulted in improved patient reported outcome. Forgetfulness was the most frequently reported reason for discontinuing SLIT treatment against grass pollen allergy.

Keywords: Adherence; Grass pollen allergy; Patient reported outcome; Real-world evidence; SLIT; Sublingual immunotherapy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Reported change in allergy symptoms when comparing the most recent grass pollen season to the season before start of Grazax treatment
Fig. 2
Fig. 2
Allergic symptoms during the most recent grass pollen season
Fig. 3
Fig. 3
Reported reason for discontinuation of Grazax treatment
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bachert C, Vestenbaek U, Christensen J, Griffiths UK, Poulsen PB. Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis—a Northern European perspective. Clin Exp Allergy. 2007;37:772–779. doi: 10.1111/j.1365-2222.2007.02706.x. - DOI - PubMed
    1. Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W, et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol. 2008;121:512–518. doi: 10.1016/j.jaci.2007.10.039. - DOI - PubMed
    1. Durham SR, Riis B. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage. Allergy. 2007;62:954–957. doi: 10.1111/j.1398-9995.2007.01402.x. - DOI - PubMed
    1. Durham SR. SQ-standardised grass tablet sublingual immunotherapy: persistent clinical benefit and progressive immunological changes during three years treatment. Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess. 2009;96:121–127. - PubMed
    1. Durham SR, Emminger W, Kapp A, Colombo G, de Monchy JG, Rak S, et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol. 2010;125:131–138. doi: 10.1016/j.jaci.2009.10.035. - DOI - PubMed

LinkOut - more resources